Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
23 04 2021
Historique:
received: 27 09 2019
accepted: 06 02 2020
entrez: 23 4 2021
pubmed: 24 4 2021
medline: 15 12 2021
Statut: ppublish

Résumé

It is not clear if the European Systematic Coronary Risk Evaluation algorithm is useful for identifying prevalent subclinical atherosclerosis in a population of apparently healthy individuals. Our aim was to explore the association between the risk estimates from Systematic Coronary Risk Evaluation and prevalent subclinical atherosclerosis. The design of this study was as a cross-sectional analysis from a population-based study cohort. From the general population, the Swedish Cardiopulmonary Bioimage Study randomly invited individuals aged 50-64 years and enrolled 13,411 participants mean age 57 (standard deviation 4.3) years; 46% males between November 2013-December 2016. Associations between Systematic Coronary Risk Evaluation risk estimates and coronary artery calcification and plaques in the carotid arteries by using imaging data from a computed tomography of the heart and ultrasonography of the carotid arteries were examined. Coronary calcification was present in 39.5% and carotid plaque in 56.0%. In men, coronary artery calcium score >0 ranged from 40.7-65.9% and presence of carotid plaques from 54.5% to 72.8% in the age group 50-54 and 60-65 years, respectively. In women, the corresponding difference was from 17.1-38.9% and from 41.0-58.4%. A doubling of Systematic Coronary Risk Evaluation was associated with an increased probability to have coronary artery calcium score >0 (odds ratio: 2.18 (95% confidence interval 2.07-2.30)) and to have >1 carotid plaques (1.67 (1.61-1.74)). Systematic Coronary Risk Evaluation estimated risk is associated with prevalent subclinical atherosclerosis in two major vascular beds in a general population sample without established cardiovascular disease or diabetes mellitus. Thus, the Systematic Coronary Risk Evaluation risk chart may be of use for estimating the risk of subclinical atherosclerosis.

Sections du résumé

BACKGROUND
It is not clear if the European Systematic Coronary Risk Evaluation algorithm is useful for identifying prevalent subclinical atherosclerosis in a population of apparently healthy individuals. Our aim was to explore the association between the risk estimates from Systematic Coronary Risk Evaluation and prevalent subclinical atherosclerosis.
DESIGN
The design of this study was as a cross-sectional analysis from a population-based study cohort.
METHODS
From the general population, the Swedish Cardiopulmonary Bioimage Study randomly invited individuals aged 50-64 years and enrolled 13,411 participants mean age 57 (standard deviation 4.3) years; 46% males between November 2013-December 2016. Associations between Systematic Coronary Risk Evaluation risk estimates and coronary artery calcification and plaques in the carotid arteries by using imaging data from a computed tomography of the heart and ultrasonography of the carotid arteries were examined.
RESULTS
Coronary calcification was present in 39.5% and carotid plaque in 56.0%. In men, coronary artery calcium score >0 ranged from 40.7-65.9% and presence of carotid plaques from 54.5% to 72.8% in the age group 50-54 and 60-65 years, respectively. In women, the corresponding difference was from 17.1-38.9% and from 41.0-58.4%. A doubling of Systematic Coronary Risk Evaluation was associated with an increased probability to have coronary artery calcium score >0 (odds ratio: 2.18 (95% confidence interval 2.07-2.30)) and to have >1 carotid plaques (1.67 (1.61-1.74)).
CONCLUSION
Systematic Coronary Risk Evaluation estimated risk is associated with prevalent subclinical atherosclerosis in two major vascular beds in a general population sample without established cardiovascular disease or diabetes mellitus. Thus, the Systematic Coronary Risk Evaluation risk chart may be of use for estimating the risk of subclinical atherosclerosis.

Identifiants

pubmed: 33891684
pii: 6248055
doi: 10.1177/2047487320909300
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

250-259

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Carl J Östgren (CJ)

Department of Medical and Health Sciences, Linköping University, Sweden.

Stefan Söderberg (S)

Department of Public Health and Clinical Medicine, Umeå University, Sweden.

Karin Festin (K)

Department of Medical and Health Sciences, Linköping University, Sweden.

Oskar Angerås (O)

Department of Cardiology, Sahlgrenska University Hospital, Sweden.
Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden.

Göran Bergström (G)

Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden.
Department of Clinical Physiology, Sahlgrenska University Hospital, Sweden.

Anders Blomberg (A)

Department of Public Health and Clinical Medicine, Umeå University, Sweden.

John Brandberg (J)

Department of Radiology, Sahlgrenska University Hospital, Sweden.
Department of Radiology, University of Gothenburg, Sweden.

Kerstin Cederlund (K)

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Sweden.

Mats Eliasson (M)

Department of Public Health and Clinical Medicine, Umeå University, Sweden.

Gunnar Engström (G)

Department of Clinical Sciences in Malmö, Lund University, Sweden.

David Erlinge (D)

Department of Clinical Sciences Lund, Lund University, Sweden.
Skåne University Hospital, Sweden.

Erika Fagman (E)

Department of Radiology, Sahlgrenska University Hospital, Sweden.
Department of Radiology, University of Gothenburg, Sweden.

Emil Hagström (E)

Department of Medical Sciences, Uppsala University, Sweden.
Uppsala Clinical Research Center, Uppsala University, Sweden.

Lars Lind (L)

Department of Medical Sciences, Uppsala University, Sweden.

Maria Mannila (M)

Department of Medicine, Karolinska University Hospital, Sweden.

Ulf Nilsson (U)

Department of Public Health and Clinical Medicine, Umeå University, Sweden.

Jonas Oldgren (J)

Department of Medical Sciences, Uppsala University, Sweden.
Uppsala Clinical Research Center, Uppsala University, Sweden.

Ellen Ostenfeld (E)

Department of Clinical Sciences Lund, Lund University, Sweden.
Skåne University Hospital, Sweden.

Anders Persson (A)

Department of Medical and Health Sciences, Linköping University, Sweden.
Centre of Medical Image Science and Visualization, Linkoping University, Sweden.
Department of Radiology, Linköping University, Sweden.

Jonas Persson (J)

Department of Clinical Sciences, Danderyd University Hospital, Sweden.

Margaretha Persson (M)

Department of Clinical Sciences in Malmö, Lund University, Sweden.
Skåne University Hospital, Sweden.

Annika Rosengren (A)

Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden.
Sahlgrenska University Hospital, Sweden.

Johan Sundström (J)

Department of Medical Sciences, Uppsala University, Sweden.
The George Institute for Global Health, University of New South Wales, Australia.

Eva Swahn (E)

Department of Medical and Health Sciences, Linköping University, Sweden.
Department of Cardiology, Linköping University, Sweden.

Jan E Engvall (JE)

Department of Medical and Health Sciences, Linköping University, Sweden.
Centre of Medical Image Science and Visualization, Linkoping University, Sweden.
Department of Clinical Physiology, Linköping University, Sweden.

Tomas Jernberg (T)

Department of Clinical Sciences, Danderyd University Hospital, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH